A 12-year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns

Hong Bin Liu¹, Zong Da Meng¹, Jing Chen Ma², Chang Quan Han², Ying Lin Zhang², Zhan Chun Xing², Yu Wei Zhang², Yu Zhong Liu² and Hui Lin Cao²

Abstract

AIM To understand the anti-HBs persistence and the long-term preventive efficacy in rural newborns after vaccination with plasma-derived hepatitis B vaccine.

METHODS In the time of expanded program on immunization (EPI), the newborns were vaccinated with 10 µg × 3 doses of hepatitis B vaccine and 762 newborns who were HBsAg negative after primary immunization were selected for cohort observation from 1986 to 1998. Their serum samples were detected qualitatively and quantitatively for hepatitis B infecting markers, including HBsAg, anti-HBs and anti-HBc by SPRIA Kits. The annual HBsAg positive conversion rate was counted by life-table method.

RESULTS ① The anti-HBs positive rate was 94.44% for the babies born to HBsAg negative mothers and 84.21% for those born to HBsAg positive mothers in the 1st year after immunization, and dropped to 51.31% and 52.50% in the 12th year respectively. GMT value was dropped from 31.62 to 3.13 and 23.99 to 3.65 in the 2nd to the 12th year respectively. There was a marked drop in GMT at the 3rd to the 5th year, and in anti-HBs positive rate at the 9th to the 10th year. ② In the period of 12 years observation, the person-year HBsAg positive conversion rates were 0.12% (5/4150.0) in newborns born to HBsAg negative mothers and 0.20% (1/508.0) in those born to HBsAg positive mothers, and none of the HBsAg positive converted children became HBsAg chronic carriers. Compared with the baseline before immunization, the protective rates were 97.19% and 95.32% respectively.

CONCLUSION The protective efficacy of plasma-derived hepatitis B vaccine persisted at least 12 years, and a booster dose seems not necessary within at least 12 years after the primary three-doses immunization to newborns born to HBsAg negative mothers.

INTRODUCTION

In recent years, many studies on the efficacy of hepatitis B plasma-derived vaccine demonstrated that the anti-HBs antibodies were declined gradually, but the protective rate for children vaccinated with three-doses hepatitis B vaccine was still more than 80%[1,2]. To understand the anti-HBs persistence and long-term efficacy in newborn, a 1-12 year experimental study on hepatitis B plasma-derived vaccine was carried out among newborns vaccinated with three doses 10 µg/L vaccine in rural area.

MATERIALS AND METHODS

Objects

Newborn infants from one township in Zhengding County, Hebei Province, were vaccinated during 1986-1989. A total of 762 infants who were HBsAg negative after primary vaccination were selected for cohort observation, of them 688 born to HBsAg-negative mothers, and 74 to HBsAg carrier mothers. The annual HBsAg positive conversion rate for newborn infants was 4.72% before immunization.

Vaccine and immunization

Hepatitis B plasma-derived vaccine was produced by Beijing Institute of Biological Products. The newborns were immunized with three doses vaccine at 0mo, 1mo and 6mos of age by well-trained...
nurses between 1986-1989 under the rural area immunization program launched in 1986. The first dose was vaccinated at 2.7 mo-0.3 mo (95% CI). The coverage rate of vaccination with a complete course of 3-dose hepatitis B vaccine was 91.5%.

**Blood collection and laboratory study**

Blood samples were collected from infants by venipuncture at intervals of one or two years. Serum HBsAg, anti-HBs and anti-HBc were tested by RIAs from Beijing Institute of Biological Product. Those who showed HBsAg (S/N value ≥2.1), anti-HBc (CO/S value ≥2.0) or both were defined as HBV infection, and anti-HBs (S/N value ≥2.1) as immunity.

**RESULTS**

**Persistence of anti-HBs after vaccination**

The 688 new born babies were born to HBsAg negative mothers, and 74 were born to HBsAg positive mothers. Anti-HBs positive rate was gradually dropped from 94.44% to 51.31% and 84.21% to 52.50% in the 1st-12th year respectively. GMT value was dropped from 31.62 to 3.13 and 23.99 to 3.65 in the 2nd-12th year respectively. There was a marked drop in GMT value at the 3rd-5th year, and in anti-HBs positive rate at the 9th-10th year. Compared with infants born to HBsAg negative mothers, GMT value was lower in infants born to HBsAg positive mothers (Table 1).

**HBsAg annual positive conversion rate for vaccinated children**

In the period of 12 years follow-up, 5 children born to HBsAg-negative mothers became HBsAg positively converted. Two of them occurred at the 5th year and the rest occurred at the 9th-10th year. The person-year HBsAg positive conversion on rate was 0.12% (5/4150.0). One child born to HBsAg positive mothers became HBsAg positively converted, and it occurred at the 5th year. The person-year HBsAg positive conversion rate was 0.20% (1/508.0). None of 6 HBsAg positive converted children became HBsAg chronic carriers (Table 2). Compared with the baseline before immunization, the protective rates were 97.19% and 95.32% respectively (Table 3).

**Table 1 Dynamic change of anti-HBs positive rate and GMT after vaccination**

| Years vaccinated | Mothers HBsAg (-) | Mothers HBsAg (+) |  |
|------------------|-------------------|-------------------|------|
|                  | No.tested | Positive rate (%) | GMT (S/N) | No.tested | Positive rate (%) | GMT (S/N) |  |
| 1                | 18        | 94.44             | 26.30     | 19        | 84.21             | 15.14     |  |
| 2                | 134       | 89.55             | 31.62     | 48        | 95.83             | 23.99     |  |
| 3                | 232       | 89.22             | 26.30     | 51        | 92.16             | 22.91     |  |
| 4                | 344       | 85.17             | 18.62     | 51        | 73.33             | 6.46      |  |
| 6                | 296       | 79.39             | 9.77      | 54        | 79.63             | 8.71      |  |
| 7                | 608       | 80.76             | 9.33      | 58        | 86.21             | 7.78      |  |
| 8                | 599       | 78.30             | 6.17      | 56        | 75.00             | 5.25      |  |
| 9                | 517       | 57.79             | 4.17      | 48        | 60.24             | 3.47      |  |
| 10               | 412       | 50.24             | 3.09      | 23        | 34.78             | 2.51      |  |
| 11               | 173       | 51.80             | 2.86      | 30        | 56.00             | 2.91      |  |
| 12               | 424       | 51.30             | 3.13      | 20        | 52.50             | 3.65      |  |

χ²m-h 226.12  P value <0.001

**Table 2 HBsAg person-year positive conversion for immunized children**

| Follow-up (year) | Mother HBsAg (-) | Mother HBsAg (+) |  |
|------------------|------------------|------------------|------|
|                  | No. person year | No. positively converted | Annual positive conversion rate | No. person year | No. positively converted | Annual positive conversion rate |  |
| 1                | 9.0              | 0                 | 0.00       | 9.5       | 0                 | 0.00       |  |
| 2                | 76.0             | 0                 | 0.00       | 33.5      | 0                 | 0.00       |  |
| 3                | 183.0            | 0                 | 0.00       | 49.5      | 0                 | 0.00       |  |
| 4                | 288.0            | 0                 | 0.00       | 51.0      | 0                 | 0.00       |  |
| 5                | 454.0            | 2                 | 0.44       | 55.5      | 1                 | 1.80       |  |
| 6                | 428.0            | 0                 | 0.00       | 57.0      | 0                 | 0.00       |  |
| 7                | 450.0            | 0                 | 0.00       | 56.0      | 0                 | 0.00       |  |
| 8                | 602.0            | 0                 | 0.00       | 57.0      | 0                 | 0.00       |  |
| 9                | 482.0            | 2                 | 0.34       | 52.0      | 0                 | 0.00       |  |
| 10               | 486.0            | 1                 | 0.20       | 35.5      | 0                 | 0.00       |  |
| 11               | 292.5            | 0                 | 0.00       | 26.5      | 0                 | 0.00       |  |
| 12               | 298.5            | 0                 | 0.00       | 25.0      | 0                 | 0.00       |  |
| Total            | 4150.0           | 5                 | 0.12       | 508.0     | 1                 | 0.20       |  |
**DISCUSSION**

The ultimate strategy for newborn vaccination with hepatitis B vaccine is controlling and eliminating hepatitis B. Many specialists think that newborns should be vaccinated within 24 hours which is more effective for preventing HBV mother-infant transmission. In recent studies, some reports say that the risk of HBV infection should increase with the decline of anti-HBs positive rate and GMT value after vaccination of hepatitis B vaccine. Thus, a booster of hepatitis B vaccine should be given. In this study, anti-HBs positive rate declined with age, so was GMT value. The anti-HBs positive rate declined markedly from the 9th to the 10th year, and maintained 50% or so at the 10th-12th year. GMT value declined markedly from the 3rd to the 5th year. Therefore, if we only analyze anti-HBs positive rate and GMT value, it is the best schedule to revaccinate at 3-5 years of age after the primary 3-doses regimen.

With the long-term observation of hepatitis B vaccine, more and more scholars think that the protective efficacy for immune responder could persist several years, even if anti-HBs may have declined to undetectable levels. This may be due to the good memory response to hepatitis B vaccination. The higher anti-HBs level after booster immunization dropped quickly with time, and at the end of 3-5 years dropped to the level of children who had not received booster immunization. The evaluation of the immune efficacy of hepatitis B vaccine should induce antibody level, but the dynamic of HBsAg and the chronic carrier rate during ten years of immunization. Cao et al. reported that anti-HBs level declined with years after vaccination and HBsAg positive conversion had not been detected among children born to HBsAg negative mothers in Hunan. Our study indicated that none of children born to HBsAg negative mother became HBsAg chronic carrier within 12 years after vaccination with hepatitis B vaccine, although a few children were infected with HBV and positive for HBsAg. The protective rate to those newborns born to HBsAg negative mother was still more than 95% within 12 years. We believed that long-term efficacy of hepatitis B vaccine was better and the children would have benefited from life-long hepatitis B vaccine. A booster dose seems unnecessary for children born to HBsAg negative mothers within 12 years after primary 3-dose regimen. It was reported by Cao et al. that HBsAg positive conversion children born to HBsAg carrier mothers may become HBsAg chronic carriers after vaccination with hepatitis B vaccine, and most of them occurred at 2-3 years of age. In our study, only 1 of 74 children born to HBsAg carrier mother became HBsAg positively converted, but did not become HBsAg chronic carrier within 12 years after vaccination. In order to improve the immune efficacy for those children born to HBsAg positive mothers, the dynamic of HBsAg carrier rate should be observed further in vaccinated children on a large scale.

**REFERENCES**

1. Yuan JD. Observation on efficacy of health children immunized with China hepatitis B vaccine. *Shandong Weisheng Fangyib*. 1987; 2:27-30
2. Maupas P, Chiron JP, Barin F, Courcaget P, Goudeau A, Perrin J, Denis F, Diop-Mar I. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). *Lancet*. 1981; 1:289-292
3. Courcaget P, Yvonnet B, Chotard J, Sar M, Vincelot P, N’doye R, Diop-Mar I, Chiron JP. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). *Lancet*. 1986; ii:1143-1145
4. Jilg W, Schmidt M, Deinhart F. Immune response to hepatitis B revaccination. *J Med Virol*. 1988;24:377-384
5. Yang JY, Wang SS, Li RC, Li YP, Gong J, Nong Y, Chen XR, Cao HL, Liu CB, Xu ZY. The efficacy of HB vaccine and reactivation of anti-HBs by booster at 7th year after neonates vaccination. *Zhonghua Shiyan He Linchuang Bingdu Xue Za Zhi*. 1995;9(Suppl): 47-50
6. Cao HL, Liu CB, Xia GL, Yan TQ, Ma JC, Li RC, Ou Yang PY, Liu YX, Zhang MT, Wang JJ, Gong J. A cohort study on immune persistence and preventive efficacy of hepatitis B vaccine II: the dynamic change of anti-HBs levels in immunized children. *Zhonghua Shiyan He Linchuang Bingdu Xue Za Zhi*. 1995;9(Suppl): 10-12
7. Cao HL, Xu ZY, Liu CB, Xia GL, Yan TQ, Ma JC, Li RC, Liu YX, Zhang MT, Wang JJ, Yang JY, Sun YD, Zhu QR. A cohort study of immune persistence and preventive efficacy in children after hepatitis B vaccination I: the dynamic observation of HBsAg positive conversion in neonates after HB vaccine immunization. *Zhonghua Shiyan He Linchuang Bingdu Xue Za Zhi*. 1995;9(Suppl): 5-9